|
1）Goto K, Ichinose Y, Ohe Y, et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum from IPASS, a Phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol. 2012; 7: 115-21
|
|
|
|
2）Bettegowda C, Sausen M, Leary RJ, et al. Detec-tion of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6: 224ra
|
|
|
|
|
|
3）Dawson SJ, Tsui D, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med. 2013; 368: 1199-209
|
|
|
|
|
|
4）Thress KS, Paweletz CP, Felip E, et al. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M. Nat Med. 2015; 21: 560-2
|
|
|
|
|
|
5）Sequist LV, Goldman JW, Wakelee H, et al. Efficacy pf rociletinib （CO-1686） in plasma-genotyped T790M-positive NSCLC patients. J Clin Oncol. 2015; 33（suppl; abstr 8001）
|
|
|
|
|
|
6）Marchetti A, Palma JF, Felicioni L, et al. Early prediction of response to tyrosine kinase inhibitors by quantification of EGFR mutations in plasma of non-small cell lung cancer patients. J Clin Oncol. 2015; 33（suppl; abstr 8079）
|
|
|
|
|
|
7）Ahn MJ, Lee JY, Lim SH, et al. Dynamic serial monitoring of EGFR mutation in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI. J Clin Oncol. 2015; 33（suppl; abstr 8078）
|
|
|
|
|
|
8）EGFR遺伝子変異陽性・進行再発肺腺癌に対するアファチニブ療法における，digital PCR法を用いたバイオマーカー研究（第II相試験）WJOG8114LTR（UMIN000015847）
|
|
|
|
|